Peptides & the FDA review: your questions, answered

Not on the July 2026 agenda. A later review is anticipated (reported as early 2027); no official FDA date was confirmed as of July 2026.^{1 2}

No completed human clinical trials exist. The evidence is from cell and animal studies; safety and effectiveness in people are unknown.³

DiHexa is not an FDA-approved drug and has no cleared compounding pathway. It was removed from Category 2 in April 2026 but is not on the July 2026 agenda; a later review is expected.^{2 1}